Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma - The ASCO Post
Dosing and Administration for the NINLARO® (ixazomib) Regimen
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma | MedPage Today
547-Lenalidomide and dexamethasone oral | eviQ
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial - The Lancet
DRd Trial Design & Efficacy | REVLIMID® (lenalidomide)
VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX | 2 Minute Medicine
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
Relapsed Multiple Myeloma Treatment Results | KYPROLIS® (carfilzomib)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
Multiple Myeloma Support + Trials
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
ADD Velcade, Revlimid, and dex (VRd) | Int Myeloma Fn
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
REVLIMID® (lenalidomide) - Official Patient Website
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Velcade/Revlimid/Dexamethasone New Standard for Newly Diagnosed Multiple Myeloma - CancerConnect
Revlimid/ Dexamethasone : r/multiplemyeloma
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
